IsoTherapeutics specializes in the development of radiopharmaceuticals, focusing on both therapeutic and diagnostic agents for severe diseases. The company has a strong foundation in radiochemistry and radiolabeling, boasting over 100 patents related to innovative chemistry and radiopharmaceutical formulations. Their services encompass a wide range of activities, from early-stage research and proof of concept for new drug molecules to the manufacturing of these drugs in a cGMP facility for preclinical studies. This comprehensive approach ensures that clients receive support throughout the entire development process, ultimately facilitating a smoother transition to clinical trials.

The company operates state-of-the-art facilities equipped with advanced radioanalytical counting equipment, including alpha, beta, and gamma counters, as well as high-resolution gamma spectroscopy tools. IsoTherapeutics offers a variety of services, including radiochemical processing, isotope selection, and pharmacokinetics/bio-distribution studies. Their expertise extends to consulting, where they leverage their collective experience to advise clients on reducing costs and expediting the path to clinical trials. Through collaborations with various pharmaceutical and life-science companies, IsoTherapeutics has established a reputation for excellence in the field of radiopharmaceutical development.

United States

We develop novel therapeutic and diagnostic agents directed at severe diseases. Our specialty is therapeutic radiopharmaceuticals.
IsoTherapeutics has been acquired by Telix Pharmaceuticals.

IsoTherapeutics_

Company Details